These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 29246775)

  • 41. [Clinical diversity, diagnosis and treatment of hereditary amyloid neuropathy].
    Sekijima Y
    Rinsho Shinkeigaku; 2014; 54(12):953-6. PubMed ID: 25672679
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical variant of familial amyloid polyneuropathy.
    Quan D; Cohen JA
    Muscle Nerve; 2002 Sep; 26(3):417-20. PubMed ID: 12210373
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hereditary transthyretin amyloidosis caused by the rare Phe33Leu mutation.
    Björkenheim A; Szabó B; Sztaniszláv ÁJ
    BMJ Case Rep; 2020 Jan; 13(1):. PubMed ID: 31932463
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients.
    Monteiro C; Martins da Silva A; Ferreira N; Mesgarzadeh J; Novais M; Coelho T; Kelly JW
    Amyloid; 2018 Jun; 25(2):120-128. PubMed ID: 29993288
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
    Maurer MS; Elliott P; Merlini G; Shah SJ; Cruz MW; Flynn A; Gundapaneni B; Hahn C; Riley S; Schwartz J; Sultan MB; Rapezzi C;
    Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611125
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genotypic and phenotypic presentation of transthyretin-related familial amyloid polyneuropathy (TTR-FAP) in Turkey.
    Durmuş-Tekçe H; Matur Z; Mert Atmaca M; Poda M; Çakar A; Hıdır Ulaş Ü; Oflazer-Serdaroğlu P; Deymeer F; Parman YG
    Neuromuscul Disord; 2016 Jul; 26(7):441-6. PubMed ID: 27238058
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recent progress in the understanding and treatment of transthyretin amyloidosis.
    Sekijima Y
    J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy).
    Cho Y; Baranczak A; Helmke S; Teruya S; Horn EM; Maurer MS; Kelly JW
    Amyloid; 2015; 22(3):175-80. PubMed ID: 26193961
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Familial amyloidotic polyneuropathy and transthyretin.
    Nagasaka T
    Subcell Biochem; 2012; 65():565-607. PubMed ID: 23225017
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current and future treatment of amyloid neuropathies.
    Adams D; Cauquil C; Theaudin M; Rousseau A; Algalarrondo V; Slama MS
    Expert Rev Neurother; 2014 Dec; 14(12):1437-51. PubMed ID: 25416603
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Amyloid heart disease mimicking hypertrophic cardiomyopathy.
    Mörner S; Hellman U; Suhr OB; Kazzam E; Waldenström A
    J Intern Med; 2005 Sep; 258(3):225-30. PubMed ID: 16115295
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Transthyretin Familial Amyloid Polyneuropathy - Disease Profile of a Multisystem Disorder].
    Niemietz C; Röcken C; Schilling M; Stypmann J; Uhlig CE; Schmidt HH
    Dtsch Med Wochenschr; 2018 Mar; 143(6):427-430. PubMed ID: 29544239
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vitreous amyloidosis in two sisters as the indication of transthyretin-related familial form of systemic amyloidosis among liver transplantation candidates.
    Niemczyk R; Brydak-Godowska J; Kecik D; Wagner T; Lewandowski P; Kecik M; Zygier D; Ołdakowska-Jedynak U
    Transplant Proc; 2009 Oct; 41(8):3085-7. PubMed ID: 19857683
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tafamidis polyneuropathy amelioration requires modest increases in transthyretin stability even though increases in plasma native TTR and decreases in non-native TTR do not predict response.
    Monteiro C; Mesgarzadeh JS; Anselmo J; Fernandes J; Novais M; Rodrigues C; Powers DL; Powers ET; Coelho T; Kelly JW
    Amyloid; 2023 Mar; 30(1):81-95. PubMed ID: 36178172
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical and genetic findings in eight Israeli patients with transthyretin-associated familial amyloid polyneuropathy.
    Leibou L; Frand J; Sadeh M; Lossos A; Kremer E; Livneh A; Yarnitsky D; Herman O; Dabby R
    Isr Med Assoc J; 2012 Nov; 14(11):662-5. PubMed ID: 23240369
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Variable presentations of TTR-related familial amyloid polyneuropathy in seventeen patients.
    Cappellari M; Cavallaro T; Ferrarini M; Cabrini I; Taioli F; Ferrari S; Merlini G; Obici L; Briani C; Fabrizi GM
    J Peripher Nerv Syst; 2011 Jun; 16(2):119-29. PubMed ID: 21692911
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
    Merkies IS
    Neurology; 2013 Apr; 80(15):1444-5. PubMed ID: 23569001
    [No Abstract]   [Full Text] [Related]  

  • 58. Modeling familial amyloidotic polyneuropathy (Transthyretin V30M) in Drosophila melanogaster.
    Berg I; Thor S; Hammarström P
    Neurodegener Dis; 2009; 6(3):127-38. PubMed ID: 19372706
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Electrochemical skin conductance in hereditary amyloidosis related to transthyretin V30M - a promising tool to assess treatment efficacy?
    Castro J; Costa J; de Castro I; Conceição I
    Amyloid; 2018 Dec; 25(4):267-268. PubMed ID: 30773060
    [No Abstract]   [Full Text] [Related]  

  • 60. TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies.
    Adams D; Cauquil C; Labeyrie C; Beaudonnet G; Algalarrondo V; Théaudin M
    Expert Opin Pharmacother; 2016; 17(6):791-802. PubMed ID: 26800456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.